摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-methyl 4-(2-(4-bromobenzylthio)-3-(4-fluoro-3-nitrophenyl)acryloyl)benzoate | 1035202-15-3

中文名称
——
中文别名
——
英文名称
(E)-methyl 4-(2-(4-bromobenzylthio)-3-(4-fluoro-3-nitrophenyl)acryloyl)benzoate
英文别名
methyl 4-[(E)-2-[(4-bromophenyl)methylsulfanyl]-3-(4-fluoro-3-nitrophenyl)prop-2-enoyl]benzoate
(E)-methyl 4-(2-(4-bromobenzylthio)-3-(4-fluoro-3-nitrophenyl)acryloyl)benzoate化学式
CAS
1035202-15-3
化学式
C24H17BrFNO5S
mdl
——
分子量
530.371
InChiKey
RBVZQGGIPAKNKY-LPYMAVHISA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.4
  • 重原子数:
    33
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.08
  • 拓扑面积:
    115
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

  • 作为产物:
    描述:
    methyl 4-(2-(4-bromobenzylthio)acetyl)benzoate 、 4-氟-3-硝基苯甲醛溶剂黄146苄胺 作用下, 以76%的产率得到(E)-methyl 4-(2-(4-bromobenzylthio)-3-(4-fluoro-3-nitrophenyl)acryloyl)benzoate
    参考文献:
    名称:
    Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase
    摘要:
    Novel (E)-alpha-benzylthio chalcones are reported with preliminary in vitro activity data indicating that several of them are potent inhibitors (comparable to imatinib, the reference compound) of BCR-ABL phosphorylation in leukemic K562 cells, known to express high levels of BCR-ABL. The ability of such compounds to significantly inhibit K562 cell proliferation suggests that this scaffold could be a promising lead for the development of anticancer agents that are able to block BCR-ABL phosphorylation in leukemic cells. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.01.051
点击查看最新优质反应信息

文献信息

  • SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF
    申请人:Reddy E. Premkumar
    公开号:US20100028368A1
    公开(公告)日:2010-02-04
    Compounds useful as antiproliferative agents according to formula (I): wherein Ar 1 , Ar 2 , Ar 3 , m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
    提供了按照公式(I)定义的有用的抗增殖剂化合物,其中Ar1,Ar2,Ar3,m和n的定义如此,还提供了盐,抗体结合物,药物组合物,治疗方法和合成方法。
  • US8808702B2
    申请人:——
    公开号:US8808702B2
    公开(公告)日:2014-08-19
  • [EN] SULFIDE, SULFOXIDE AND SULFONE CHALCONE ANALOGUES, DERIVATIVES THEREOF AND THERAPEUTIC USES THEREOF<br/>[FR] ANALOGUES DE SULFURE, SULFOXYDE ET SULFONE DE CHALCONE, LEURS DÉRIVÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES
    申请人:UNIV TEMPLE
    公开号:WO2008076270A2
    公开(公告)日:2008-06-26
    [EN] Compounds useful as antiproliferative agents according to formula (I): wherein Ar1, Ar2, Ar3, m and n are as defined herein, salts, antibody conjugates, pharmaceutical compositions, methods of treatment, and synthetic methods are provided.
    [FR] La présente invention a pour objet des composés utiles en tant qu'agents antiprolifératifs selon la formule (I): dans laquelle Ar1, Ar2, Ar3, m et n sont tels que définis dans la présente description, des sels, des conjugués d'anticorps, des compositions pharmaceutiques, des procédés de traitement et des procédés de synthèse.
  • Design, synthesis and evaluation of (E)-α-benzylthio chalcones as novel inhibitors of BCR-ABL kinase
    作者:M.V. Ramana Reddy、Venkat R. Pallela、Stephen C. Cosenza、Muralidhar R. Mallireddigari、Revathi Patti、Marie Bonagura、May Truongcao、Balaiah Akula、Shashidhar S. Jatiani、E. Premkumar Reddy
    DOI:10.1016/j.bmc.2010.01.051
    日期:2010.3
    Novel (E)-alpha-benzylthio chalcones are reported with preliminary in vitro activity data indicating that several of them are potent inhibitors (comparable to imatinib, the reference compound) of BCR-ABL phosphorylation in leukemic K562 cells, known to express high levels of BCR-ABL. The ability of such compounds to significantly inhibit K562 cell proliferation suggests that this scaffold could be a promising lead for the development of anticancer agents that are able to block BCR-ABL phosphorylation in leukemic cells. (C) 2010 Elsevier Ltd. All rights reserved.
查看更多